Staff Reports
Americans from left to right suddenly agree on something politicians love: tell the market to stop charging so much. A new Wall Street Journal poll shows huge bipartisan backing for price‑cap ideas — caps on prescription drugs, a 10% cap on credit‑card APRs, and limits on child‑care costs — and now lawmakers and the White House are racing to turn that popularity into policy. That should make conservatives worried, and everyone who thinks economics still matters sit up straight.
The poll that started it — and why politicians pounced
The Wall Street Journal poll found overwhelming support across parties: near‑unanimous backing for capping prescription‑drug prices, roughly three‑quarters supporting a 10% cap on credit‑card interest, and large majorities favoring limits on child‑care charges. That kind of public appetite is irresistible. So Senator Bernie Sanders and Senator Josh Hawley teamed up on a 10% APR bill (S.381), and the White House rolled out TrumpRx, a federal website pointing consumers to discounted drug purchases. It’s a strange coalition, but political theater rarely asks for ideological purity — it asks for applause.
The quick fix that bites back
Price caps sound simple: put a law on the books and watch bills shrink. Trouble is, prices do real work. They signal costs, risks and supply. Cap credit cards at 10% and lenders don’t vanish into thin air — they stop lending to higher‑risk people, cut limits, or close accounts. JPMorgan Chase CEO Jamie Dimon and other banking leaders warn blunt caps would choke off credit for people who need it most, and international examples show that happens in practice. Chile’s experience with rate ceilings, for instance, cut access to credit for marginal borrowers. Same deal with child care: costs reflect labor, regulations and demand. If you cap prices without fixing supply, you get empty slots, not relief.
Drugs and innovation: short relief, long regret
Prescription‑drug caps are politically irresistible because people see immediate savings at checkout. But drug development is costly and risky. Studies — including work summarized by leading economic researchers — show that deep or permanent price controls tend to reduce expected returns on research and development. That doesn’t sound urgent when you’re saving on a refill today, but over time fewer breakthroughs mean worse outcomes for patients. The 1970s clearly taught us that sweeping price and wage controls produce shortages and distortions; medicine’s innovation pipeline is no exception.
Design matters — pick smart tools, not political stunts
The real debate should be about design. Temporary, targeted programs — vouchers, subsidies, negotiated discounts, means‑tested help — can help people without wrecking markets. A federal portal that steers consumers toward discounts is a different animal than a legal, economy‑wide price ceiling. The political temptation is to deliver a visible “win” today and let someone else pay for tomorrow’s shortages. Conservatives should call that out plainly: if you want to help families, expand supply, cut needless regulation, and design aid narrowly. If you want headlines, pass caps and watch scarcity write the sequel.
